No CrossRef data available.
Article contents
Treatment of the attention deficit disorder (residual type) with moclobemide
Published online by Cambridge University Press: 16 April 2020
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Letter to the editor
- Information
- Copyright
- Copyright © Elsevier, Paris 1995
References
Parquet, PJServant, DBailly, Det al.Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type.A propos of a case Encephale 14/6 1988 439–41Google Scholar
Wenker, PHGarfinkel, BDAttention Deficit Hyperactivity Disorder: Adult Manifestations Kaplan, HISadock, BJ 5th edComprehensive Textbook of Psychiatryvol 2 Baltimore: Williams and Wilkins, 1989; 1837–41Google Scholar
Biederman, JNewcorn, JSpnah, SComorbidity of Attention Deficit Hyperactivity Disorder with conduct, depressive, anxiety and other disorders Am J Psychiatry 148/5 1991 564–77Google ScholarPubMed
Shakim, WOAsarnow, RFHess, E et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state Compr Psychiatry 31/5 1990 416–25CrossRefGoogle Scholar
Trott, GEFriese, HJMenzel, Met al.Use of Moclobemide in children with attention deficit hyperactivity disorder. Psyche-pharmacology 1992; 106: S134–6CrossRefGoogle ScholarPubMed
You have
Access
Comments
No Comments have been published for this article.